TFE3 and Parkinson disease: Our observation that LRRK2 inhibition increases the expression and nuclear localization of TFE3 and TFEB suggests that LRRK2 inhibitors under development for Parkinson’s disease might have wider impacts in the treatment of other diseases associated with lysosome deficiencies and/or defects in innate immunity.